<PAGE> 1
FORM 10-QSB
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
(x) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1997
------------------
or
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 for the transition period from____________ to _________________.
Commission File Number:
0-22390
-------
U.S. MEDICAL SYSTEMS, INC.
--------------------------
Delaware 68-0206382
-------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
7600 Burnet Road, Suite 350, Austin, TX 78757
- --------------------------------------- -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code. . . . . . (512) 795-0440
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.
YES _X_ NO ____
Number of shares outstanding of the issuer's common stock, as of
September 30, 1997: 2,873,823
<PAGE> 2
U.S. MEDICAL SYSTEMS, INC.
INDEX
PART I FINANCIAL INFORMATION PAGE
Item 1. Financial Statements
Unaudited Condensed Consolidated Balance Sheets -
September 30, 1997 and June 30, 1997 3
Unaudited Condensed Consolidated Statements of
Operations - For the three months ended
September 30, 1997 and September 30, 1996 4
Unaudited Condensed Consolidated Statements of
Cash Flows - For the three months ended September 30, 1997
and September 30, 1996 5
Notes to the Unaudited Condensed Consolidated
Financial Statements 6
Item 2. Management's Discussion and Analysis of Financial
Conditions and Results of Operations 7
PART II. OTHER INFORMATION
Signature 12
Page 2 of 12
<PAGE> 3
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
U.S. MEDICAL SYSTEMS, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
September 30 June 30
1997 1997
----------------- ----------------
<S> <C> <C>
ASSETS
Current Assets
Cash and cash equivalents $ 207,000 $ 275,000
Accounts receivable 180,000 16,000
Inventory 11,000 59,000
Prepaid expenses 6,000 5,000
----------------- ----------------
TOTAL CURRENT ASSETS 404,000 355,000
Other Assets
Property and equipment, net 13,000 16,000
Intangible assets, net 1,000 -
----------------- ----------------
TOTAL OTHER ASSETS 14,000 16,000
================= ================
TOTAL ASSETS $ 418,000 $ 371,000
================= ================
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable $ 39,000 $ 31,000
Accrued liabilities 26,000 29,000
Current portion of long-term debt due to stockholders 50,000 50,000
----------------- ----------------
TOTAL CURRENT LIABILITIES 115,000 110,000
----------------- ----------------
TOTAL LIABILITIES 115,000 110,000
----------------- ----------------
Stockholders' Equity
Common stock, 20,000,000 shares authorized, $ .01
par value, 2,873,823 issued and
outstanding September 30, 1997
and 2,332,023 issued and outstanding June 30, 1996 29,000 29,000
Additional paid-in capital 7,039,000 7,039,000
Accumulated deficit (6,765,000) (6,807,000)
----------------- ----------------
TOTAL STOCKHOLDERS' EQUITY 303,000 261,000
TOTAL LIABILITIES AND STOCKHOLDERS'
================= ================
EQUITY $ 418,000 $ 371,000
================= ================
</TABLE>
The accompanying notes are an integral part of these unaudited
consolidated financial statements.
Page 3 of 12
<PAGE> 4
U.S. MEDICAL SYSTEMS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATION
<TABLE>
<CAPTION>
For the three months For the three months
ended September 30 ended September 30
1997 1996
-------------------- ------------------
<S> <C> <C>
Net Sales $ 213,000 $ 103,000
Cost of sales (83,000) (74,000)
-------------------- ------------------
GROSS PROFIT 130,000 29,000
Costs and expenses
General and administrative 80,000 75,000
Selling and marketing 5,000 8,000
Research and development 1,000 6,000
Depreciation and amortization 3,000 21,000
-------------------- ------------------
TOTAL COST AND EXPENSES 89,000 110,000
-------------------- ------------------
PROFIT (LOSS) FROM OPERATIONS 41,000 (81,000)
Other income (expense)
Interest income 2,000 -
Interest expense (1,000) (21,000)
Miscellaneous income (expense), net - -
-------------------- ------------------
TOTAL OTHER INCOME (EXPENSE) 1,000 (21,000)
-------------------- ==================
NET PROFIT (LOSS) $ 42,000 $ (102,000)
==================== ==================
Net income (loss) per share $ 0.01 $ (0.08)
==================== ==================
Weighted average shares outstanding 2,873,823 1,215,591
</TABLE>
The accompanying notes are an integral part of these unaudited
consolidated financial statements.
Page 4 of 12
<PAGE> 5
U.S. MEDICAL SYSTEMS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
For the three months For the three months
ended September 30 ended September 30
1997 1996
------------------- ------------------
<S> <C> <C>
Cash flows from operating activities
Net Income (Loss) $ 42,000 $ (101,000)
Adjustments to reconcile net loss to net cash used for
operating activities:
Depreciation and amortization 3,000 19,000
Write off of excess inventory 21,000
Changes in assets and liabilities
Accounts receivable (164,000) 33,000
Inventories 27,000 39,000
Prepaid expenses and other assets (1,000) (1,000)
Accounts payable and accrued liabilities 5,000 6,000
------------------- ------------------
Net cash used for operating activities (67,000) (5,000)
------------------- ------------------
Cash flows from investing activities:
Proceeds from sales of furniture and equipment - 2,000
Additions to patents (1,000) -
------------------- ------------------
Net cash provided by (used for) investing activities (1,000) 2,000
------------------- ------------------
Increase (decrease) in cash (68,000) (3,000)
Cash and cash equivalents at beginning of year 275,000 22,000
------------------- ------------------
Cash and cash equivalents at end of period $ 207,000 $ 19,000
=================== ==================
</TABLE>
The accompanying notes are an integral part of these unaudited
consolidated financial statements.
Page 5 of 12
<PAGE> 6
U.S. MEDICAL SYSTEMS, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
- -------------------------------------------------------------------------------
1. ORGANIZATION
U.S. MEDICAL SYSTEMS, INC. (the "Company") (formally Medical Polymers
Technologies, Inc.), through its wholly-owned subsidiary U.S. Medical,
Inc., develops, produces and markets products directed at the
over-the-counter consumer market and products related to infection
prevention for the professional dental health care industry.
The Company's current cash resources have not been sufficient to
support the Company's debt interest payments and extensive consumer
promotion of existing products. As such, the Company is focusing its
strategy on the Miracle Grip(R) and PDS(R) Clean products. Due to the
extensive capital requirements for consumer advertising, the Company
will continue to focus in 1998 its two revenue producing products. In
December 1996, the Company completed a restructuring and $853,000 of
its long term debt was converted to equity.
2. BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements
have been prepared in accordance with the rules and regulations of the
Securities and Exchange Commission and, accordingly, do not include all
information and footnotes required under generally accepted accounting
principles for complete financial statements. In the opinion of
management, these interim condensed consolidated financial statements
contain all adjustments (consisting of normal recurring adjustments)
considered necessary for a fair presentation of the financial position
of the Company as of September 30, 1997, and the results of the
Company's operations and its cash flows for the three months ended
September 30, 1997 and 1996. These condensed consolidated financial
statements should be read in conjunction with the Company's Annual
Report on Form 10-KSB filed on September 26, 1997.
3. INVENTORIES
At September 30, 1997 and June 30, 1997, inventories consisted
primarily of finished products, work in progress and raw chemicals. The
balance of inventory consisted of packaging materials for Miracle
Grip(R).
4. LONG TERM DEBT
The Company completed a private placement of 10% subordinated debt with
warrants to existing shareholders on March 1, 1995 for $805,000. This
private placement included one stock purchase warrant exercisable for
approximately 2.9 shares of $.01 par value Common Stock of the Company
for every $1.00 of principal. One cent of each dollar invested was
attributed to the purchase of the warrants and $0.99 was attributed to
the notes. The warrants were exercisable at any time after September 1,
1995 until February 27, 2000 at an exercise price of $0.15 per share of
common stock, subject to adjustment. Terms of debt were 10% interest
only to be paid March 1, 1996; 10% interest and one-half of the
principal to be paid March 1, 1997; and 10% interest and the balance of
the principal was to be paid March 1, 1998. The amount of the proceeds
Page 6 of 12
<PAGE> 7
attributable to the warrants ($8,050) was recorded as a discount to
debt (to be amortized over the life of the debt) and an increase to
additional paid-in capital. Offering expenses of $35,000 were incurred
and recorded as an intangible asset in the financial statements.
However, the remaining unamoritized offering expense of $21,000 were
written off in December 1996, when the debt was converted to equity.
These expenses were being amortized over the life of the debt. On
November 19, 1996, stockholders approved a reorganization plan which
converted $853,000 of the principle and interest of this debt to
equity. On December 17, 1,110,983 shares of common stock was issued to
satisfy the above debt. Warrants related to this private placement were
canceled as part of the reorganization. There is one debt holder
remaining which represents $49,500 of principle and approximately
$12,000 in interest. The Company is seeking to restructure this debt.
5. REORGANIZATION PLAN
In order to address the Company's financial problem and return the
Company to a stable financial condition, management, with the approval
of the Board of Directors, devised a Reorganization Plan. The
Reorganization Plan called for the cancellation of all the indebtedness
of the Company to its noteholders through an offer to exchange the
outstanding notes for the Company's Common Stock. On June 10, 1996, the
Vancouver Stock Exchange indicated that it had no objection to the
proposed debt settlement with the noteholders. Written approval was
secured by twenty-three of the noteholders. The stockholders approved
the debt settlement on November 19, 1996. Stockholders also approved,
as part of the reorganization, a consolidation of the Company's shares
on a one-for-seven reverse split and approved a change of the name of
the Company to U. S. Medical Systems, Inc. Other items the Company took
action on as part of the reorganization, which did not require
stockholder approval, were: cancellation of 3,177,325 escrowed shares
and a private placement which raised approximately $270,900. On
December 17, 1996, the Vancouver Stock Exchange approved the
reorganization and the company began trading as U.S. Medical Systems,
Inc. on the Vancouver Stock Exchange (Symbol: USS) and the NASD
Bulletin Board (Symbol: USME). On January 22, 1997, the Vancouver Stock
Exchange approved the private placement. Since the private placement
was not approved until January 1997, $213,275 received in December 1996
from investors in the private placement was recorded as U.S. Medical
Systems, Inc. liabilities and included in accrued liabilities in the
December 31, 1996 financial statements. An additional $57,625 was
received in January 1997 and 541,800 shares of common stock were
issued.
6. NET INCOME (LOSS) PER SHARE
Net (loss) per share is computed by dividing net income (loss) by the
weighted average number of common shares and common share equivalents
(if dilutive) during each period. As required by accounting principles
generally accepted in the United States, issued and outstanding shares
of common stock which are held in escrow are excluded from the weighted
average number of common and common equivalent shares because the
release of such shares is contingent upon the Company reaching certain
financial goals which have not yet been attained. On September 30,
1997, the weighted average, excluding escrow shares, was 2,873,823 for
the three month period.
Page 7 of 12
<PAGE> 8
ITEM 2.
This quarterly report on Form 10-QSB contains certain forward-looking statements
and information relating to the Company and its subsidiaries that are based on
the beliefs of the Company's management as well as assumptions made by and
information currently available to the Company's management. When used in this
report, the words "anticipate," "believe," "estimate" and "intend" and words or
phrases of similar import, as they relate to the Company or its subsidiaries or
Company management, are intended to identify forward-looking statements. Such
statements reflect the current risks, uncertainties and assumptions related to
certain factors including, without limitations, competitive factors, general
economic conditions, customer relations, relationships with vendors,
governmental regulation and supervision, seasonality, distribution networks,
product introductions and acceptance, technological change, changes in industry
practices, onetime events and other factors described herein. Based upon
changing conditions, should any one or more of these risks or uncertainties
materialize, or should any underlying assumptions prove incorrect, actual
results may vary materially from those described herein as anticipated,
believed, estimated, expected or intended. The Company does not intend to update
these forward-looking statements.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The discussion below analyzes changes in the consolidated operating results and
financial condition of the Company during its first quarter of fiscal 1997 and
1998.
GENERAL
The Company experienced an increase in net sales, a profit from operation and a
profit for the fiscal quarter ended September 30, 1997. Net sales increased 107%
during the first quarter from $103,000 in 1997 to $213,000 in 1998. Operating
profits increased from $29,000 in the first quarter of fiscal 1997 to $130,000
in fiscal 1998 first quarter. Net profit improved from a loss of $102,000 in
1997 to a profit of $42,000 for the reporting quarter. The Company's gross
margin increased to 61.0% in 1998 from 28.2% in 1997. The increase in gross
margin was due primarily to the increased sales of the PDS(R) product line in
this quarter. Losses are anticipated in 1998 as the Company continues its
efforts to obtain increased market acceptance for its Miracle Grip(R) product
line, and expand the PDS(R) line to other markets.
The increase in sales for the current period is attributable to the sales in
PDS(R) line. Likewise, increases in operating profits are related to the
increase in sales and to decreases in overall expenses. It is expected that
overhead expenses will increase over the next period due to the expenses related
to the Company's annual meeting and pre-payment of insurance and manufacturing
costs.
The Company continues to seek increases in sales of the Miracle Grip(R) product
line through major food and drug chains in the United States. Likewise, the
Company has completed a direct mail test in areas of the country where Miracle
Grip(R) is not sold and may continue to pursue sales through that channel as
well beginning a market effort on the internet at miraclegrip.com. The Company
will require additional capital to manufacture and market existing and future
products developed internally.
In late 1996, the Board of Directors completed a reorganization plan to
restructure the Company and convert debt to equity. There can be no assurance
that the reorganization approved by stockholders in November of 1996 and by the
Vancouver Stock Exchange will improve financial performance. Likewise, there can
be no assurance that the Company will be able to sustain operations through
1998, convert its remaining raw materials and packaging inventories into salable
products or successfully
Page 8 of 12
<PAGE> 9
market its products. The Company has previously
disclosed that it might seek to sell one or all of its existing product lines
and seek to acquire or merge with an existing company. Management continues to
pursue this strategy.
The Company has suffered significant net losses, has a substantial accumulated
deficit and has generated significant negative cash flows from operations.
Marketing expenses and costs to maintain inventory during fiscal 1998 will
require significant cash resources. The Company obtained $270,900 in December
1996 and January 1997 in connection with the private placement of equity and
warrants. However, there can be no assurance that the additional cash resources
will enable the Company to sustain operations in the next fiscal year, convert
its remaining raw materials and packaging inventories into salable products or
successfully market its products. In consideration of this, additional financing
may be required in order to continue to fund operations. See the discussion
under "Liquidity and Capital Resources" below.
RESULTS OF OPERATIONS
The following table sets forth, for the periods indicated, certain items from
the Company's Condensed Consolidated Financial Statements of Income, expressed
as a percentage of revenue:
Three Months ended
September 30
1997 1996
- --------------------------------- -------------------- ------------------
NET SALES 100.0% 100.0%
COSTS AND EXPENSES
Cost of sales (39.0%) (71.8%)
General and administrative (37.6%) (72.8%)
Selling and marketing (2.3%) (7.8%)
Research and development (0.5%) (5.8%)
Depreciation and amortization (1.4%) (20.4%)
-------------------- ------------------
OPERATING EXPENSES (80.8%) (178.6%)
INCOME (LOSS) from operations 19.2% (78.6%)
Total other income (expense): 0.5% (20.4%)
NET INCOME (LOSS) 19.7% (99.0%)
- --------------------------------- -------------------- ------------------
THREE MONTHS ENDED SEPTEMBER 30, 1997 COMPARED TO THREE MONTHS ENDED
SEPTEMBER 30, 1996
Net sales for the three months ended September 30, 1997, increased 107.0% to
$213,000 from $103,000 for the same period last year. Approximately two-thirds
of the 1997 sales were related to PDS(R) Clean product for the dental market
which has higher margins, lower cost of goods and lower marketing costs. Sales
of the polymer film product line decreased 39.0% from last year's period. This
was due to the loss of the REVCO DS account due to their merger with CVS. Net
sales of the discontinued stick technology decreased 98.0% compared to the
corresponding fiscal 1997 period. Sales of the PDS(R) line were up in this
period. However, management does not expect this to recur as sales of that
product are sporadic.
Page 9 of 12
<PAGE> 10
Cost of goods sold as a percentage of net sales decreased to 39.0% from 71.8%
primarily as the result of a shift in mix of sales, with increased sales in the
PDS(R) technology compared to the film technology product and higher gross
margins of products sold in the current period. Gross margins are expected to
fluctuate in future quarters depending on whether the polymer film technology or
the PDS(R) line is the more significant contribution to revenues.
General and administrative expenses increased by $5,000, or 6.7% in the first
quarter 1998 period compared to the 1997 period primarily as a result of an
increase in professional fees and bad debts. Although management plans to
continue cost cutting efforts in this area, overhead expenses are expected to
increase in the next quarter.
The decrease of $3,000 or 37.5% in sales and marketing expenses in the first
quarter 1998 period was largely associated with a credit of promotional and
advertising cost on the Miracle Grip(R) product line from the previous quarter.
Currently six brokers representing the Company market the Miracle Grip(R)
product. Limited advertising on the internet will begin in 1998.
Research and development expenses decreased to less than $1,000 in the current
period due to discontinuation of testing by NewForm Development Labs.
Interest expense decreased to $1,000 due to the conversion of $853,000 of
principle and interest. Interest income increased in the period to $2,000.
As a result of the above activities, the Company's performance improved from a
loss $102,000 in the fiscal 1997 period, or $(0.08) per share to a profit of
$42,000, or $0.01 per share in fiscal 1998's first quarter. If the Company is
able to effectively implement internet advertising support for Miracle Grip(R)
in 1998, sales volumes for the Miracle Grip(R) product line may improve.
However, the Company operates in a highly competitive industry with companies
that are better established in the market place and have vastly greater
resources than the Company. Therefore, there can be no assurances that demand
for the Company's Miracle Grip(R) product line will grow.
LIQUIDITY AND CAPITAL RESOURCES
Working capital at September 30, 1997 was $289,000 compared to a $245,000 at
June 30, 1997. The current ratio was 3.5 compared to 3.2 at June 30, 1997. The
increase in working capital is due to a profitable first quarter.
There were no capital expenditures in this period.
Total long term debt outstanding was $50,000, not including accrued interest on
the debt, at September 30, 1997 of $12,300. Interest on the debt is being
accrued monthly.
In December 1996, the Company completed a reorganization plan which included the
conversion $853,000 of principle and interest through November 1, 1996 to
equity. This transaction was approved by 23 of the 24 noteholders representing
94% of the Company's outstanding debt. The Company is negotiating to restructure
the remaining noteholder.
Management believes the reorganization, including the debt conversion to equity,
together with existing cash resources and net proceeds from sales of its
products and the completed private placement will be satisfactory to fund
operations for the next three to five months. There can be no assurance that the
Page 10 of 12
<PAGE> 11
Company will be able to obtain financing on acceptable terms, if at all, to fund
operations beyond that time frame. Currently, management is continuing to pursue
its strategy to obtain new sources of revenue by reviewing acquisition or merger
opportunities.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None.
ITEM 2. CHANGE OF SECURITIES
None
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
ITEM 5. OTHER INFORMATION
None
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
27 - Financial Data Schedule
99 - News Release dated November 12, 1997
(b) Reports on Form 8-K
None
Page 11 of 12
<PAGE> 12
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
U.S. MEDICAL SYSTEMS, INC.
THE REGISTRANT
Date: November 12, 1997
/s/ LEE COOKE
-------------
Lee Cooke
Chairman of the Board, President
and Chief Executive Officer
(Principal Financial Officer
Page 12 of 12
<PAGE> 13
EXHIBIT INDEX
27 - Financial Data Schedule
99 - News Release dated November 12, 1997
<TABLE> <S> <C>
<ARTICLE> 5
<CIK> 0000898770
<NAME> U.S. MEDICAL SYSTEMS, INC.
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JUN-30-1998
<PERIOD-START> JUL-01-1997
<PERIOD-END> SEP-30-1997
<CASH> 207,000
<SECURITIES> 0
<RECEIVABLES> 180,000
<ALLOWANCES> 5,000
<INVENTORY> 11,000
<CURRENT-ASSETS> 404,000
<PP&E> 14,000
<DEPRECIATION> 0
<TOTAL-ASSETS> 418,000
<CURRENT-LIABILITIES> 115,000
<BONDS> 0
0
0
<COMMON> 29,000
<OTHER-SE> 303,000
<TOTAL-LIABILITY-AND-EQUITY> 418,000
<SALES> 213,000
<TOTAL-REVENUES> 0
<CGS> 83,000
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 5,000
<INTEREST-EXPENSE> 1,000
<INCOME-PRETAX> 42,000
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 42,000
<EPS-PRIMARY> 0.01
<EPS-DILUTED> 0
</TABLE>
<PAGE> 1
EXHIBIT 99
NEWS
RELEASE
U.S. MEDICAL SYSTEMS, INC.
(FORMALLY MEDICAL POLYMERS TECHNOLOGIES, INC.)
FOR INFORMATION CONTACT: TRADING SYMBOLS:
Lee Cooke NASD OTC Bulletin Board -USME
Chief Executive Officer VSE -USS
FOR IMMEDIATE RELEASE
NOVEMBER 12, 1997
U.S. MEDICAL SYSTEMS, INC. REPORTS FIRST QUARTER RESULTS
AUSTIN, TX -- U.S. Medical Systems, Inc. today announced results for its 1998
fiscal year first quarter ended September 30, 1997. For the quarter, this
bio-medical technology company posted a net profit of $42,000 or $0.01 cents a
share on net revenue of $213,000 compared to the prior year net loss of $102,000
or $0.08 cents a share, on revenue of $103,000.
Mr. Lee Cooke, Chairman and Chief Executive Officer stated, "This is the best
financial performance the Company has experienced in over two years." This
improvement resulted from increased orders of the Company's dental cleaner
introduced to the market in 1993. However, the sales of Miracle Grip(R) denture
adhesive dropped by 39% over the same quarter last year. Mr. Cooke expected
overall sales to be weaker in the second quarter of 1998 due to this decline in
Miracle Grip(R) sales.
"The Company continues to pursue its strategy to add other sources of revenue or
secure a merger partner." stated Cooke.
Certain statements contained herein are "forward-looking statements" (as such
term is defined in the Private Securities Litigation Reform Act of 1995). These
statements are based upon the belief of the Company's management, as well as
assumptions made beyond information currently available to Company's management.
Because such "forward-looking statements" are subject to risks and
uncertainties, actual results may differ materially from those expressed or
implied. Such forward-looking statements include, but are not limited to,
competitive factors, general economic condition, customer relations,
relationships with vendors, government supervision and regulation, product
introductions and acceptance, technological changes, changes in industry
practices, and other factors discussed in filings made by the Company with the
Securities and Exchange Commission.
The mission of U.S. Medical Systems, Inc. is to develop and commercialize
innovative products, concentrating on its polymer based technologies. The
Company seeks to become a leader in the market niches it enters by providing
unique value-added products.
--Table Follows--
_______________________________________________________________________________
7600 Burnet Road, Suite 350, TEL (512) 458-3335 FAX (512) 458-3343
Austin, TX 78757
<PAGE> 2
TABLE
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
U.S. MEDICAL SYSTEMS, INC.
Quarter Ended
-------------------------------------------
September 30
1997 1996
-------------------------------------------
(Unaudited)
Sales $213 $103
Net Profit (Loss) $42 $(102)
Gain per share $0.01 $(0.08)
Weighted Avg shares o/s 2,874 1,216
The Vancouver Stock Exchange has neither approved nor disapproved the
information contained herein.
_______________________________________________________________________________
7600 Burnet Road, Suite 350, TEL (512) 458-3335 FAX (512) 458-3343
Austin, TX 78757
